Innoviva, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INVA research report →
Companywww.inva.com
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA.
- CEO
- Pavel Raifeld
- IPO
- 2004
- Employees
- 127
- HQ
- Burlingame, CA, US
Price Chart
Valuation
- Market Cap
- $1.64B
- P/E
- 3.27
- P/S
- 3.87
- P/B
- 1.23
- EV/EBITDA
- 3.05
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 76.20%
- Op Margin
- 14.85%
- Net Margin
- 118.91%
- ROE
- 47.59%
- ROIC
- 2.93%
Growth & Income
- Revenue
- $425.13M · 18.52%
- Net Income
- $271.17M · 1059.22%
- EPS
- $4.02 · 986.49%
- Op Income
- $163.75M
- FCF YoY
- 3.92%
Performance & Tape
- 52W High
- $25.15
- 52W Low
- $16.52
- 50D MA
- $22.92
- 200D MA
- $20.80
- Beta
- 0.38
- Avg Volume
- 743.25K
Get TickerSpark's AI analysis on INVA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 4, 26 | Raifeld Pavel | other | 312,500 |
| May 4, 26 | Raifeld Pavel | other | 126,646 |
| May 4, 26 | DiPaolo Mark | other | 9,786 |
| May 4, 26 | DiPaolo Mark | other | 10,000 |
| May 4, 26 | Zhen Marianne | other | 12,766 |
| May 4, 26 | Zhen Marianne | other | 31,500 |
| May 4, 26 | Schlesinger Sarah J. | other | 9,786 |
| May 4, 26 | Schlesinger Sarah J. | other | 10,000 |
| May 4, 26 | Basso Stephen | other | 93,750 |
| May 4, 26 | Basso Stephen | other | 37,994 |
Our INVA Coverage
We haven't published any research on INVA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate INVA Report →